When the maker of a branded drug updates the safety information on its product labeling, makers of generic versions of that drug must wait until the Food and Drug Administration approves the new labeling before they can update theirs, but that could soon change under a rule proposed by the FDA.
New Senate legislation introduced Tuesday that would restore consumers’ ability to use pre-tax dollars from flexible spending accounts and health savings accounts to purchase over-the-counter medicines without first seeing a doctor has been jointly endorsed by the National Association of Chain Drug Stores and the National Community Pharmacists Association.
Sen. David Vitter, R-La., is holding up a vote on a measure that would strengthen regulations on compounding pharmacies in order to alter a provision of the Patient Protection and Affordable Care Act, according to published reports.
U.S. Sens. Pat Roberts, R-Kan., and Mary Landrieu, D-La., on Tuesday introduced legislation that repeals a portion of Obamacare that prohibits people from using their medical savings account funds to buy over-the-counter medications.
A proposal by the Texas State Board of Pharmacy to eliminate the required ratio of pharmacy technicians to pharmacists in retail pharmacies in the state has drawn mixed responses from professional and industry trade groups.
Mylan expects to be the first to market with a generic version of a drug for treating patients with gout, the company said Friday, though its filing has triggered a lawsuit from the makers of the branded version.
The Food and Drug Administration has released a new video that warns consumers against buying drugs from rogue-internet pharmacies, part of the ongoing effort by the agency to keep fake and contaminated drugs out of the U.S. supply chain.
Actavis is seeking Food and Drug Administration approval for a generic drug used to treat acne, triggering a lawsuit in a federal court from the maker of the branded version, the company said Thursday.
The Food and Drug Administration is using long-term strategies to address drug shortages when they appear and requiring manufacturers to notify the agency if a shortage is at risk of happening, under a new plan announced Thursday.
Earlier this year, the Food and Drug Administration approved a new drug for treating cystic fibrosis for patients who have a specific genetic mutation, but that also treats the underlying cause of the disease rather than the disease itself.